Cannabis firm Cresco Labs beats Q3 revenue expectations

Cresco Labs

05/11/2025 11:37

Overview

Cresco Labs Q3 revenue of $165 mln beats analyst expectations

Company reports Q3 net loss of $22 mln, impacted by debt refinancing costs

Company expands into Kentucky, plans product launch in Germany

Outlook

Cresco Labs plans to expand with new dispensaries in Ohio and Kentucky

Company anticipates product launch in Germany to drive growth

Cresco Labs prepared to lead cannabis industry growth and consolidation

Result Drivers

DEBT REFINANCING - Co refinanced debt to strengthen balance sheet and reduce total debt

MARKET EXPANSION - New dispensaries in Ohio and expansion into Kentucky are key growth drivers

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$165 mln
$163.70 mln (7 Analysts)
Q3 Net Income
-$22 mln
Q3 Adjusted EBITDA
$40 mln
Q3 Adjusted Gross Margin
48.80%
Q3 Gross Profit
$79 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Cresco Labs Inc is C$2.00, about 24.5% above its November 4 closing price of C$1.51

Press Release: ID:nBw6rMMD1a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)